
    
      This is a Phase 1C randomized, placebo controlled, double-blinded, in-patient trial of a
      single oral dose of 300 mg of SQ109 given daily for 14 consecutive days to evaluate the
      safety, tolerability and pharmacokinetics of SQ109 in normal healthy male and female subjects
      18-45 years of age.

      Each subject will receive 300 mg of SQ109 or placebo.
    
  